Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials

Robert A Fletcher; William G Herrington; Rajiv Agarwal; Kaitlin J Mayne; Clare Arnott; Meg J Jardine; Kenneth W Mahaffey; Vlado Perkovic; Natalie Staplin; David C Wheeler; Glenn M Chertow; Hiddo J L Heerspink; Brendon L Neuen

doi:10.2215/CJN.0000000000000470

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials

Clin J Am Soc Nephrol. 2024 Apr 16. doi: 10.2215/CJN.0000000000000470. Online ahead of print.

Authors

Robert A Fletcher¹, William G Herrington^{2

3

4}, Rajiv Agarwal⁵, Kaitlin J Mayne^{2

6}, Clare Arnott^{1

7

8}, Meg J Jardine^{9

10}, Kenneth W Mahaffey¹¹, Vlado Perkovic^{1

12}, Natalie Staplin^{2

3}, David C Wheeler^{1

13}, Glenn M Chertow¹⁴, Hiddo J L Heerspink^{1

15}, Brendon L Neuen^{1

16}

Affiliations

¹ The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
² Medical Research Council Population Health Research Unit at the University of Oxford, Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, United Kingdom.
³ Clinical Trial Service Unit and Epidemiologic Studies Unit (CTSU), NDPH, University of Oxford, Oxford, United Kingdom.
⁴ Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
⁵ Indiana University School of Medicine and VA Medical Center, Indianapolis, Indiana.
⁶ School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, United Kingdom.
⁷ Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁸ Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
⁹ NHMRC Clinical Trials Centre, University of Sydney, New South Wales, Australia.
¹⁰ Department of Renal Medicine, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
¹¹ Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, California.
¹² Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia.
¹³ Department of Renal Medicine, University College London, London, United Kingdom.
¹⁴ Departments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Stanford, California.
¹⁵ Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
¹⁶ Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.

PMID: 38622766
DOI: 10.2215/CJN.0000000000000470

Abstract

Clinical Trial registry name and registration number: ClinicalTrials.gov Identifiers: NCT02065791 (CREDENCE), NCT03036150 (DAPA-CKD), NCT03594110 (EMPA-KIDNEY).

Associated data

ClinicalTrials.gov/NCT03036150
ClinicalTrials.gov/NCT03594110
ClinicalTrials.gov/NCT02065791